Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for the Treatment of Metastatic Melanoma Patients
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; T cell replacement therapy (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 21 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 21 May 2017 Status changed from recruiting to discontinued due to toxicity of cyclophosphamide.
- 27 Nov 2013 New trial record